# Phase 2 Pulmonary Disease, Chronic: 32 recruiting (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 32 trials in phase 2 for Pulmonary Disease, Chronic Obstructive that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 2 Pulmonary Disease, Chronic Obstructive trials: 32 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 1 row a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-2/pulmonary-disease-chronic-obstructive

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 32
- Recruiting or not yet: 32
- Read on: November 19, 2026

## Trials

The 25 newest of 32, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 6, 2026 | NCT07923591 | Study of Treprostinil Administered Via Soft Mist Inhaler (SMI) in Participants With Pulmonary Hypertension Associated With Chronic... | United Therapeutics | Phase 2 | Not yet recruiting | Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07923591) |
| November 4, 2026 | NCT07915791 | A Study to Assess the Efficacy and Safety of Co-administration of GSK3862995B With GSK5784283 in Adult Participants With Moderate to Severe... | GlaxoSmithKline | Phase 2 | Recruiting | Pulmonary Disease, Chronic Obstructive | 279 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07915791) |
| October 26, 2026 | NCT07896252 | Phase 2b Efficacy and Safety Study of AERO-007, an Inhaled LABA+LAMA Combination for Nebulization Delivery in COPD Patients | AeroRx Therapeutics Inc. | Phase 2 | Recruiting | COPD, Chronic Obstructive Pulmonary Disease (COPD), Lung Disease Chronic, Lung Diseases, Obstructive | 64 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07896252) |
| October 13, 2026 | NCT07871357 | Urolithin A Supplementation During Pulmonary Rehabilitation in Patients With COPD | Sponsor not shown (see the record) | Phase 2 | Not yet recruiting | Chronic Obstructive Pulmonary Disease (COPD) | 198 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07871357) |
| August 12, 2026 | NCT07759245 | A Study of Brenipatide (LY3537031) in Adult Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD) | Eli Lilly and Company | Phase 2 | Recruiting | Pulmonary Disease, Chronic Obstructive | 606 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07759245) |
| August 5, 2026 | NCT07747805 | GLP-1 Agonists for Lung Function Improvement and Muscle Restoration in COPD | The Cleveland Clinic | Phase 2 | Not yet recruiting | COPD, Obesity & Overweight, Sarcopenia | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07747805) |
| July 28, 2026 | NCT07730281 | PRA-216 COPD Safety and Biomarker Study | Prana Therapies Inc | Phase 2 | Recruiting | Chronic Obstructive Pulmonary Disease (COPD) | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07730281) |
| July 24, 2026 | NCT07725939 | A Study of 24 to 52 Weeks Treatment to Evaluate The Efficacy And Safety of Galvokimig in Study Participants With Moderate-to-Severe Chronic... | UCB Biopharma SRL | Phase 2 | Recruiting | Chronic Obstructive Pulmonary Disease With Chronic Bronchitis | 402 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07725939) |
| July 15, 2026 | NCT07705737 | Rademikibart IV for Acute Asthma and COPD Exacerbation | Connect Biopharm LLC | Phase 2 | Recruiting | Asthma Acute, COPD Exacerbation Acute | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07705737) |
| July 6, 2026 | NCT07684820 | To Evaluate the Effect of EXPD-101/FXS7553 Compared With Placebo in Patients With COPD Over 52 Weeks of Treatment | Expedition Therapeutics, Inc | Phase 2 | Recruiting | Chronic Obstructive Pulmonary Disease (COPD) | 600 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07684820) |
| June 12, 2026 | NCT07646587 | A Study of WIN378 in Participants With Moderate to Severe COPD (Sirius) | Sponsor not shown (see the record) | Phase 2 | Recruiting | COPD (Chronic Obstructive Pulmonary Disease) | 105 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07646587) |
| June 10, 2026 | NCT07640451 | A Clinical Trial to Evaluate the Efficacy and Safety of HRS-9821 Inhalation Suspension in Patients With Moderate to Severe Chronic... | Guangdong Hengrui Pharmaceutical Co., Ltd | Phase 2 | Recruiting | COPD | 90 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07640451) |
| April 9, 2026 | NCT07519499 | Phase II Clinical Study to Evaluate the Efficacy and Safety of XKH001 Injection | Zhejiang Kanova Biopharmaceutical Co., LTD | Phase 2 | Not yet recruiting | COPD | 75 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07519499) |
| February 27, 2026 | NCT07441226 | Umbilical Cord Mesenchymal Stem Cells as Adjuvant Therapy in Group E COPD Patients | Sponsor not shown (see the record) | Phase 2 | Recruiting | Chronic Obstructive Pulmonary Disease (COPD) | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07441226) |
| February 20, 2026 | NCT07425210 | Long-Term Safety and Efficacy of HSK39004 Dry Powder Inhaler in COPD | Haisco Pharmaceutical Group Co., Ltd. | Phase 2 | Not yet recruiting | Chronic Obstructive Lung Disease (COLD) | 300 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07425210) |
| February 18, 2026 | NCT07418736 | A Phase II Study of CM326 in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Phase 2 | Recruiting | Chronic Obstructive Pulmonary Disease | 318 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07418736) |
| January 20, 2026 | NCT07351734 | A Phase IIa, Randomized, Double-Blind, Placebo-Controlled Trial of JKN2403 in COPD | Joincare Pharmaceutical Group Industry Co., Ltd | Phase 2 | Recruiting | COPD (Chronic Obstructive Pulmonary Disease) | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07351734) |
| January 16, 2026 | NCT07349524 | A Study to Evaluate the Efficacy and Safety of RSS0343 Tablets in Patients With Chronic Obstructive Pulmonary Disease | Reistone Biopharma Company Limited | Phase 2 | Recruiting | Chronic Obstructive Pulmonary Disease | 300 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07349524) |
| January 2, 2026 | NCT07314242 | A Study to Investigate the Biomarkers of Hemay005 in Adult Participants With Moderate to Severe COPD | Ganzhou Hemay Pharmaceutical Co., Ltd | Phase 2 | Not yet recruiting | COPD (Chronic Obstructive Pulmonary Disease) | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07314242) |
| December 18, 2025 | NCT07292714 | A Study to Evaluate 9MW1911 in Patients With Chronic Obstructive Pulmonary Disease (COPD) | Mabwell (Shanghai) Bioscience Co., Ltd. | Phase 2 | Recruiting | Chronic Obstructive Pulmonary Disease COPD | 360 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07292714) |
| August 24, 2025 | NCT07140328 | Evaluation of the Safety and Efficacy of HSK39004 Dry Powder Inhaler and HSK39004 Inhalation Suspension in Chinese Patients With Chronic... | Haisco Pharmaceutical Group Co., Ltd. | Phase 2 | Recruiting | Chronic Obstructive Lung Disease (COLD) | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07140328) |
| July 24, 2025 | NCT07082738 | A Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease | AstraZeneca | Phase 2 | Recruiting | Chronic Obstructive Pulmonary Disease (COPD) | 987 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07082738) |
| July 10, 2025 | NCT07059091 | Clinical Trial of Omalizumab for Allergen Sensitized and Exposed Individuals With COPD | Johns Hopkins University | Phase 2 | Recruiting | Chronic Obstructive Pulmonary Disease (COPD), Allergies | 334 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07059091) |
| June 26, 2025 | NCT07037836 | Inhaled Treprostinil (Tyvaso Nebulizer) For COPD Patients With Hypoxemia | Sponsor not shown (see the record) | Phase 2 | Recruiting | COPD (Chronic Obstructive Pulmonary Disease), Hypoxemia | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07037836) |
| May 20, 2025 | NCT06980142 | A Study of CM512 in Subjects With Moderate-to-Severe Chronic Obstructive Pulmonary Disease | Keymed Biosciences Co.Ltd | Phase 2 | Not yet recruiting | Chronic Obstructive Pulmonary Disease | 204 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06980142) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| [Haisco Pharmaceutical Group Co., Ltd.](https://specstream.ai/data/clinical-trials/company/haisco-pharmaceutical-group-co-ltd) | 2 |
| University of Alberta | 1 |
| [UCB Biopharma SRL](https://specstream.ai/data/clinical-trials/company/ucb-biopharma-srl) | 1 |
| Prana Therapies Inc | 1 |
| Johns Hopkins University | 1 |
| [Guangdong Hengrui Pharmaceutical Co., Ltd](https://specstream.ai/data/clinical-trials/company/guangdong-hengrui-pharmaceutical-co-ltd) | 1 |
| Aer Therapeutics | 1 |
| [United Therapeutics](https://specstream.ai/data/clinical-trials/company/united-therapeutics) | 1 |
| [CSPC ZhongQi Pharmaceutical Technology Co., Ltd.](https://specstream.ai/data/clinical-trials/company/cspc-zhongqi-pharmaceutical-technology-co-ltd) | 1 |
| Ganzhou Hemay Pharmaceutical Co., Ltd | 1 |
| University of California, San Diego | 1 |
| AeroRx Therapeutics Inc. | 1 |
| Expedition Therapeutics, Inc | 1 |
| [GlaxoSmithKline](https://specstream.ai/data/clinical-trials/company/glaxosmithkline) | 1 |
| Connect Biopharm LLC | 1 |
| [Eli Lilly and Company](https://specstream.ai/data/clinical-trials/company/eli-lilly-and-company) | 1 |
| [Mabwell (Shanghai) Bioscience Co., Ltd.](https://specstream.ai/data/clinical-trials/company/mabwell-shanghai-bioscience-co-ltd) | 1 |
| Zhejiang Kanova Biopharmaceutical Co., LTD | 1 |
| [AstraZeneca](https://specstream.ai/data/clinical-trials/company/astrazeneca) | 1 |
| The Cleveland Clinic | 1 |
| University Medical Center Groningen | 1 |
| Reistone Biopharma Company Limited | 1 |
| VA Office of Research and Development | 1 |
| Meribank Biotech Co., Ltd. | 1 |
| Joincare Pharmaceutical Group Industry Co., Ltd | 1 |

## By country

| Country | Trials |
| --- | --- |
| United States | 14 |
| China | 11 |
| Canada | 4 |
| United Kingdom | 4 |
| Argentina | 3 |
| Denmark | 3 |
| Australia | 2 |
| Czechia | 2 |
| Germany | 2 |
| Hungary | 2 |
| India | 2 |
| Japan | 2 |
| Mexico | 2 |
| Poland | 2 |
| South Korea | 2 |
| Taiwan | 2 |
| Indonesia | 1 |
| Georgia | 1 |
| Moldova | 1 |
| Austria | 1 |
| France | 1 |
| Puerto Rico | 1 |
| Romania | 1 |
| Bulgaria | 1 |
| Chile | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Surgery centers in the United States](https://specstream.ai/data/businesses/surgery-centers/united-states)
- [Pediatric orthopedic surgery practices in the United States](https://specstream.ai/data/businesses/pediatric-orthopedic-surgery-practices/united-states)
- [Iron fabricators in the United States](https://specstream.ai/data/businesses/iron-fabricators/united-states)
- [Equipment rental companies in the United States](https://specstream.ai/data/businesses/equipment-rental-companies/united-states)
- [Business schools in the United States](https://specstream.ai/data/businesses/business-schools/united-states)
- [Wineries in the United States](https://specstream.ai/data/businesses/wineries/united-states)
